A randomized, double-blind, placebo- and active-controlled, cross over, single escalating dose study to assess the safety, tolerability and pharmacokinetics of compound G44 in healthy subjects

Trial Profile

A randomized, double-blind, placebo- and active-controlled, cross over, single escalating dose study to assess the safety, tolerability and pharmacokinetics of compound G44 in healthy subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs G 44 (Primary) ; Gabapentin
  • Indications Partial epilepsies; Postherpetic neuralgia
  • Focus Adverse reactions
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 20 Oct 2016 Status changed from not yet recruiting to discontinued.
    • 18 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top